CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Back to VTRS

Dolutegravir (DTG) 50 mg orally BID (~12 hours apart) plus TDF/3TC

Phase 2
MYLAN (VTRS)

Phase 2

Development Phase

0

Upcoming Catalysts

0

Historical Events

0

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in HIV-associated Tuberculosis

View Full Landscape
Drug Information

Target Indication

HIV-associated Tuberculosis

Clinical Trial

NCT05630872

Last updated: 8/18/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.